Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have received $5 million in funding from NCI to establish an HIV-associated Malignancy Research Center focused on lung cancer in East Africa.
John Turchi receives $2.9 million from NCI to improve effectiveness of lung cancer radiation therapy
John Turchi, a researcher at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a five-year, $2.9 million grant from NCI to develop a drug that could make radiation therapy far more effective.
The Michael J. Crescence VA Medical Center in Philadelphia and VA Boston Medical Health Center in Boston have both received $50,000 grants from SWOG Cancer Research Network and The Hope Foundation for Cancer Research.
The US Oncology Network has enrolled its 100,000th patient in the Centers for Medicare & Medicaid Innovation's Oncology Care Model.
The next-generation sequencing-based FoundationOne CDx test has received FDA approval as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes, NTRK1, NTRK2, and NTRK3, in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with Vitrakvi (larotrectinib).
FDA has approved expanded claims for the cobas EGFR Mutation Test v2 as a companion diagnostic for a broad group of therapies in the treatment of non-small cell lung cancer.
CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma.
Exact Sciences Corp. and Thrive Earlier Detection Corp. have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.
EQRx has licensed two late-stage immuno-oncology agents from CStone Pharmaceuticals. The licensing agreement covers sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1).
The StrataNGS test has received coverage under Medicare by Palmetto GBA, a Medicare Administrative Contractor, for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors.
